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Tuberculosis (TB) is the foremost cause of death
from a single infectious agent in humans. Ac-
cording to recent estimates, one person is newly
infected with TB bacilli every second worldwide,
and one third of the global population is currently
infected with TB.1
Peripheral tuberculous lymphadenitis (pTBL)
is a common manifestation of extrapulmonary TB,
accounting for about 4.0–5.1% of all TB cases and
20.3–50.0% of extrapulmonary TB.2–6 Its timely
diagnosis requires a high index of suspicion and
histologic and microbiologic analyses due to 
its indolent clinical characteristics.1,5,7 American
Thoracic Society (ATS) guidelines recommend a
6-month course of therapy for pTBL that consists
of a 2-month period of isoniazid (INH), rifampin
(RIF), ethambutol (EMB) and pyrazinamide (PZA)
followed by INH and RIF for an additional 4
months.8 Although previous studies have demon-
strated a high success rate in the treatment of pTBL
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Background/Purpose: There remains uncertainty regarding the treatment strategy for patients with peripheral
tuberculous lymphadenitis (pTBL) in areas endemic for tuberculosis. The purpose of this study was to
demonstrate the clinical features and assess the predictors of a complicated treatment course in pTBL.
Methods: A retrospective analysis of 97 pTBL patients from January 1995 through to December 2004 was
conducted. Patient characteristics with and without a complicated treatment course, defined as prolonged
treatment (> 9 months) and/or relapse, were compared for determining the predictors.
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months). Of 97 pTBL patients, six had enlarged or newly appeared lymph nodes during treatment.
Multivariate analysis indicated that low body mass index and bilateral cervical nodes were independent
determinants of a complicated treatment course with the odds ratios of 1.2 (95% CI, 1.01–1.41; p = 0.042)
and 3.9 (95% CI, 1.08–14.0; p = 0.038), respectively.
Conclusion: This study found that pTBL is more likely to occur in young female patients. For patients 
who present with bilateral cervical nodes and low body mass index, a prolonged treatment course to ensure
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ORIGINAL ARTICLE
with the 6-month regimen,9–11 many patients
undergo a prolonged treatment course or suffer
disease relapse. This study examined the clinical
features and assessed the predictors of a compli-
cated treatment course in pTBL patients in Taiwan.
Methods
Study subjects and setting
This study involved a retrospective analysis of
records of both outpatients and inpatients diag-
nosed with pTBL from January 1995 through to
December 2004 at National Taiwan University
Hospital (NTUH), a tertiary medical center in
Northern Taiwan. Diagnosis of pTBL in all subjects
was confirmed by pathology of excised peripheral
lymph nodes (LN), including cervical, supraclavic-
ular, axillary and inguinal areas, showing caseat-
ing granulomatous inflammation, with or without
positive TB culture. Patients who received complete
anti-TB therapy and follow-up at our clinics were
enrolled into the study. Patients were excluded
from the study if they exhibited non-caseating gran-
ulomatous disease (such as sarcoidosis), tissue cul-
tures indicating LN yielding non-TB Mycobacterium
and multidrug resistant TB. As the objective of this
study was to verify the effectiveness of anti-TB
therapy, patients were not enrolled if they died
for reasons other than TB at follow-up pending
the completion of the treatment course.
A chart extraction form was used to retrieve
demographic data including age, gender, body
mass index (BMI), concomitant medical illness
and clinical features. The characteristics of LN and
constitutional symptoms including fever, sweating,
loss of body weight, fatigue and respiratory symp-
toms were recorded. Initial treatment regimen,
adjustment of regimen, treatment duration, drug
side effects, microbiologic data with susceptibility
tests, and treatment response were also obtained.
All patients were followed-up for at least 1 year
after the completion of treatment to verify disease
relapse. The first episode of relapse was recorded
if more than one occurred in the same patient.
Based on clinical scenarios of treatment course,
patients were divided into two groups: uncom-
plicated and complicated. Uncomplicated was de-
fined as disease cured after a 6–9-month course of
anti-TB therapy with diminished (< 1 cm) or dis-
appeared LN and no evidence of relapse for 1 year
post-treatment. Complicated was defined as patients
with: (1) prolonged treatment course exceeding
9 months; (2) treatment failure defined as LN
persisting throughout the treatment course with-
out decreasing in size; or (3) relapse defined as
cure of disease after a 6–9-month anti-TB therapy
but new appearance of LN after completing treat-
ment and diagnosis and confirmed by pathology
and/or culture results.5,7,8,12
Statistical analysis
Data were expressed as mean ± standard deviation
and range, and for data with skewed distribution
as median and range. The χ2 test was used for
categorical variables, and Fisher’s exact test (if
appropriate) and Student’s t test for continuous
variables. Exploratory analysis of predictors for 
a complicated treatment course was performed
by comparing patient characteristics between the
two groups. Univariate analysis was performed to
determine potential predictors of a complicated
treatment course. If variables were unavailable for
more than 25% of patients, only number and
ratio were presented instead of statistical analysis.
All potential predictors were included in the full
model for exploratory analysis. Multivariate lo-
gistic regression was used to assess predictors of
a complicated treatment response. Stata Statistical
Software version 8.0 (Stata Corp., College Station,
TX, USA) was used for statistical analysis. All tests




Within a 10-year period, 119 pTBL patients were
identified, representing 3.1% of all TB cases (n =
3811) diagnosed at NTUH. Twenty-two were ex-
cluded from the analysis, 15 received no treatment,
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five were lost to follow-up, and two died during
treatment due to non-TB causes. Ninety-seven (56
female, 41 male) patients were enrolled in the study.
The ethnicity of all patients was Chinese.
Fifty-six patients (uncomplicated group) were
followed-up for a mean of 44 months (range,
12–116 months). Forty-one patients (complicated
group) received a mean of 13.6 months (range,
10–26.5 months) of anti-TB therapy, 13 of whom
relapsed with a mean elapsed time of 8.5 months
(range, 3–42 months; median, 7.8 months). No
patient in the complicated group experienced
treatment failure. The cure rate was 87% (84/97).
Age distribution was mostly in the 30–39 years
old stratum (33%), followed by 20–30 (24%),
40–49 (11%), ≥ 60 (11%), 50–59 (9%), 10–19
(8%) and 0–9 (4%), respectively. Anti-human
immunodeficiency virus (HIV)-infected patients
had a mean CD4 count of 79/mm3, of whom 81%
(17/21) had acquired immune deficiency syn-
drome (AIDS), indicated by CD4 count < 200/mL
and/or appearance of opportunistic infections.
Univariate analysis revealed that only initial BMI
significantly differed (p = 0.006), indicating its
potential value as a predictor of a complicated
treatment course (Table 1).
Clinical presentations and treatment course
Table 2 summarizes the clinical features and
treatment course for all subjects. Constitutional
symptoms were observed in 76% (16/21) of HIV-
infected patients and in 12% (5/43) of non-HIV
infected patients. Pulmonary involvement was
more common (57%) in HIV-infected patients.
Chest radiography revealed fibrocalcified lesions
in 10% of patients, mediastinal lymphadenopa-
thy in 5%, mild infiltration in 10%, advanced
(caseating infiltration or cavitation) and miliary
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Table 1. Demographic data of enrolled patients*
Total (n = 97) Uncomplicated† (n = 56) Complicated† (n = 41) p
Age (yr) 37 ± 15.5 38 ± 17.0 34 ± 13.0 0.192
(97, 7–74) (56, 7–74) (41, 15–73)
Male 41/97 (42) 25/56 (45) 16/41 (39) 0.679
Previous TB 29/94 (31) 14/54 (26) 15/40 (38) 0.264
HIV positive 21/64 (33) 9/35 (26) 12/29 (41)
Immunocompromised‡ 8/97 (8) 5/56 (9) 3/41 (7) 0.999
BMI (kg/m2) 21.1 ± 3.38 21.9 ± 3.60 20.0 ± 2.74 0.006
(87, 15.9–31.5) (51, 16.3–31.5) (36, 15.9–26.8)
*Data are presented as mean ± standard deviation (n, range) or n/N (%); †see text for definitions of uncomplicated and complicated
groups; ‡chronic liver disease, renal disease, diabetes, alcoholism or steroid use. TB = tuberculosis; HIV = human immunodeficiency
virus; BMI = body mass index.
Table 2. Clinical presentations and treatment course*
Total (n = 97) Uncomplicated† (n = 56) Complicated† (n = 41) p
Constitutional symptoms‡ 27/97 (28) 13/56 (23) 14/41 (34) 0.259
Active pulmonary TB 19/96 (16) 6/55 (10) 13/41 (25) 0.002
Sites of TB other than LN 27/96 (28) 9/55 (16) 18/41 (44) 0.005
Biopsy to treatment (d) 27 ± 29.3 30 ± 26.3 25 ± 34.7 0.441
(97, −34–133) (56, −25–133) (41, −34–121)
Initial 4-drug regimen§ 80/97 (82) 45/56 (80) 35/41 (85) 0.597
Regimen adjusted due to 30/97 (31) 15/56 (27) 15/41 (37) 0.375
drug side effects
*Data are presented as n/N (%) or mean ± standard deviation (n, range); †see text for definitions of uncomplicated and complicated
groups; ‡fever, sweats, body weight loss, fatigue and airway symptoms; §rifampin, isoniazid, ethambutol, pyrazinamide. TB = tuberculosis;
LN = lymph nodes.
lesions in 6% and TB pleurisy in 2%; all others
(67%) were normal.
Six (5 in complicated group) of 97 patients had
enlarged or newly appeared LNs during the course
of treatment at an average of 2.5 months (range,
2.0–5.5 months) after initiating therapy. Three of
five patients in the complicated group underwent
surgical intervention; all were found to have gran-
uloma pathologically, but only one was culture-
positive for Mycobacterium tuberculosis. Residual
nodes were observed in eight patients, four in
each group. Three (1 in uncomplicated group, 2 in
complicated group) had local abscess formation;
otherwise, none developed local complications
such as ulceration or sinus drainage.
Characteristics of LNs, microbiologic and
laboratory results
Patients in the complicated group had more bi-
lateral cervical LNs (p = 0.025). Median duration
from development of mass to diagnosis of pTBL
was 3.5 months (range, 0.25–60 months). In HIV-
infected patients, lymphadenopathy was of shorter
duration with a mean of 47 days versus 310 days in
non-HIV infected patients. The neck region was the
most common site of lymphadenopathy. Cervical,
submandibular, supraclavicular, axillary and in-
guinal nodes were noted in 72%, 14%, 12%, 8%
and 2% of patients, respectively. Only 54.6% of
surgical specimens were sent for TB culture, and
the yield rate was 70% positive for TB. Cultures
from HIV-infected patients had a higher percent-
age of TB positivity than cultures from non-HIV-
infected patients (93% vs. 52%, p = 0.01). As Table
3 shows, resistant strains were all identified in the
complicated group, including two strains that
were resistant to EMB, two to streptomycin (SM),
one to INH and one to RIF. Laboratory findings
revealed mild anemia with hemoglobin of 12.0 ±
2.1 g/dL and 11.6 ± 2.0 g/dL and mildly elevated
lactate dehydrogenase of 545.0 ± 422.8 U/L and
447.0 ± 155.5 U/L in uncomplicated and compli-
cated groups, respectively. Other data, including
albumin and cholesterol levels, were nonspecific.
None of the differences in laboratory findings
approached statistical significance.
Multivariate analysis of predictors of a
complicated treatment response
Results of univariate analysis indicated that BMI,
TB involving other sites, active pulmonary TB and
bilateral cervical node distribution were potential
predictors. Due to the close relationship between
active pulmonary TB and TB involving other sites,
only the former was deemed a potential predictor.
Age and gender were also analyzed in the full
model. The results showed that both low BMI and
bilateral cervical node distribution were inde-
pendent determinants of complicated treatment
course with odds ratios of 1.2 (95% CI, 1.01–1.41;
p = 0.042) and 3.9 (95% CI, 1.08–14.0; p = 0.038),
respectively (Table 4).
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Table 3. Characteristics of lymph nodes and microbiologic results
Total (n = 97) Uncomplicated† (n = 56) Complicated† (n = 41) p
Positive AFS of LN 30/96 (31) 14/56 (25) 16/40 (40) 0.126
Positive culture of LN 37/53 (70) 18/26 (69) 19/27 (70)
Any resistance in drug susceptibility 6/53 (11) 0/26 (0) 6/27 (22)
Characteristics of LN
Duration (d) 194 ± 363.2 220 ± 395.7 160 ± 316.4 0.424
(91, 7–1800) (52, 7–1800) (39, 14–1800)
Size (cm) 3.0 ± 1.88 2.8 ± 1.76 3.2 ± 2.02 0.316
(95, 0.6–10) (54, 0.6–10) (41, 1–8)
Bilateral cervical node distribution 20/97 (21) 7/56 (13) 13/41 (32) 0.025
Tenderness 33/88 (37) 19/50 (38) 14/38 (37) 0.999
*Data are presented as n/N (%) or mean ± standard deviation (n, range); †see text for definitions of uncomplicated and complicated
groups. AFS = acid-fast stain; LN = lymph nodes.
Discussion
The findings of this study indicated that lower
BMI and bilateral cervical lymphadenopathy were
predictors of a complicated treatment course in
pTBL patients. The ATS guidelines for pTBL were
also found to be applicable in TB endemic areas,
and treatment response of pTBL resembled that
of pulmonary TB.
Due to the indolent nature of pTBL, patients
often seek medical treatment only after several
months of development. From 1995 to 2002, the
incidence of TB in Taiwan increased from 50 to
74.6 per 100,000 persons, representing 11,000–
16,000 new cases yearly.13 Although the results
are partially explained by the strict regulation by
National Health Insurance Policy since 1997, the
annual incidence of TB is still high according to
the Centers for Disease Control in Taiwan. This in-
creased incidence accounts for the high prevalence
of TB infection history in the study population.
Also consistent with previous reports5,6,12,14–16
was the predominance of young adult female
subjects with pTBL. The higher proportion of
young adults suggests that TB lymphadenitis is
an entity of early post-primary TB reactivation.12
Several studies have described the association
between development of TB and impaired host
immunity.2,17–22 HIV infection was the most com-
monly mentioned, in which CD4 counts were
usually < 50/mm3.1,2,7,17 The clinical features of
TB in HIV-infected patients dramatically differed
from those in immunocompetent hosts.18–20 Most
reflected a clinical syndrome of HIV infection
rather than of TB infection. The results of this
study indicated that HIV-infected patients had 
a shorter course of development of lymphadenopa-
thy, higher positive TB culture rates and more fre-
quent pulmonary involvement. These findings
may have been due to the heavy burden of TB
bacilli with rapid spread under the condition of
impaired immune defense.
Previous studies indicate that BMI is lower 
in pulmonary TB patients than in healthy 
controls.23,24 BMI is also known to be lower in
HIV-infected adults with TB infection than in
non-HIV-infected adults.25 The lower BMI reflects
the magnitude of malnutrition that is closely re-
lated to the integrity of immune defense.26 Another
finding of the current study is that patients with
bilateral cervical node distribution are more likely
to have a complicated treatment course. The same
findings can be observed in patients with TB in
other sites including pulmonary involvement.
Together, these data imply that either the extent of
TB infection or the burden of TB bacilli is attribut-
able to an unsatisfactory treatment course.
The presentations in these patients were mostly
asymptomatic except for slowly enlarging, painless
cervical masses. Physical examination typically re-
vealed firm, discrete or confluent masses. These
findings are consistent with those of previous stud-
ies, except for a drain sinus tract that was noted
in 5–10% of patients, and some who presented
with fistula.7,27,28 Since pTBL is indolent in nature,
excessive delay in diagnosis or treatment is not
uncommon.29,30 The diagnosis of patients in this
study was based on pathologic findings of excised
LNs and/or tissue cultures. In certain situations,
a surgical procedure might postpone treatment
due to pending pathology results. Culture results
also require a delay of several weeks. The tuberculin
Features and predictors of complicated treatment course in pTBL
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Table 4. Multivariate analysis for predictors of complicated treatment course
Odds ratio 95% confidence interval p
Age 1.00 0.97–1.03 0.701
Gender 0.57 0.21–1.57 0.279
Body mass index* 1.19 1.01–1.41 0.042
Active pulmonary TB 1.88 0.53–6.76 0.329
Bilateral cervical LN 3.88 1.08–14.0 0.038
*Risk ratio is presented as per unit decrease of kg/m2. TB = tuberculosis; LN = lymph nodes.
skin test has been proposed as a diagnostic tool
for pTBL.5 However, this test was not performed
because massive Bacillus Calmette-Guérin vacci-
nation and the high prevalence of TB infection
history in the general population makes the test
less useful. Culture for Mycobacterium spp. is a crit-
ical step in treating TB infection. However, surgical
specimens are rarely sent for microbiologic culture,
which highlights the need to implement a stan-
dard procedure for managing pTBL.5,7,12
ATS guidelines indicate that a 6-month regi-
men consisting of INH and RIF is effective for TB
treatment, and a 9- to 12-month regimen is needed
for infection in the central nervous system.8 Due
to the high incidence of INH resistance (4.7–12.0%
of primary resistance) in Taiwan,13 the treatment
strategy for newly diagnosed TB is comprised of
a four-drug (INH, EMB, RIF, PZA) regimen for
the initial 2 months followed by INH, EMB and
RIF for an additional 4 months.31 Further, the ATS
guidelines indicate that prolongation of therapy
should be considered if clinical improvement is
slow.8 However, the categories slow to respond and
paradoxical response are not clearly distinguishable,
especially in pTBL. In this study, 6% of cases had
enlargement or newly appearing LNs during initial
treatment. A literature review of pTBL5,6,10–12,14–17
disclosed that newly appearing LNs, enlargement
of existing nodes or nodes becoming fluctuant
occurs in up to 20% of pTBL patients at a mean of
3.5 months after the initiation of therapy.5,10,12,32
Residual nodes were also noted in 4–10% of cases
after completion of therapy, although most of them
were free from microbiological relapse.5,6,12,17,32
The overall cure rate was 89–100%, but treatment
duration, even in recent decades, usually exceeds
6 months. It is crucial that clinicians carefully
differentiate between post-therapy paradoxical
expansion and treatment failure. Otherwise, pa-
tients may be subject to a higher risk of anti-TB
drug-related side effects.
There are several limitations to this study. First,
the incidence of pTBL might have been under-
estimated due to cases detected by fine needle 
aspiration not being enrolled. Second, due to 
the unavailability of certain biochemical data, the
effects of these criteria on complicated treatment
course was not analyzed, and only patient char-
acteristics were considered. Third, treatment strate-
gies depend on the judgment of the clinicians,
and misclassification of treatment response might
occur. Finally, most of our patients did not receive
directly observed treatment strategy (DOTS); thus,
possible lack of adherence to treatment may have
played a role in determining patient outcome.
In conclusion, this study of the clinical features
and treatment course of pTBL patients indicate
that young adult females with asymptomatic cer-
vical lymphadenopathy should be examined for
pTBL, especially in TB endemic areas. The relatively
low proportion of surgical specimens being sent for
mycobacterial culture highlights the need to im-
plement a standard procedure for managing pTBL.
A prolonged treatment course should be consid-
ered in patients who present with bilateral cervical
nodes and low BMI to ensure disease control.
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